Skip to main content
EnglishEN
European Commission logo print header

Integrated and standardized NGS workflows for Personalised therapy

Project description

DEENESFRITPL

New workflows for personalised therapy in cancers

For clinical oncology providers, knowing the potential and the limitations of DNA sequencing can be critical for delivering genomic-supported care for patients. Thanks to technological advances a high-throughput of Next Generation Sequencing (NGS) can be applied in standard clinical practice. Amassed protocols for the analysis and interpretation of NGS data and knowledge bases, will allow clinicians to provide more targeted care for their patients. The EU funded Instand-NGS4P project will develop innovative NGS workflows from sample-pre-analytics focusing on conditions of patients for routine diagnostic of common-and-rare juvenile-and-adult cancers. A fully integrated and standardised NGS will be created with cooperation with leading medical centres with experience in NGS platforms in research, European patient advocacy groups and standardisation organisations.

Objective

Instand-NGS4P is a 65-month PCP project federating 7 leading medical centers (two are coordinating ERNs) as buyers’ group with major experience in using different NGS platforms in research and routine diagnostics. The consortium is further strengthened by European patient advocacy groups, a standardization organization and partners participating in the European infrastructures BBMRI-ERIC, ELIXIR as well as several NGS-related EU programs to cover all technical aspects and transversal needs & requirements. Driven by patient and clinical needs, innovative NGS workflows from sample-pre-analytics to medical decision making will be developed. The modular design of the workflow will particularly enable SEMs to contribute, and provides flexibility to adopt emerging user needs and technologies. Specifications will address regulatory requirements for IVDs and refer to international standards and requests development of reference materials and implementation of EQA schemes covering the whole workflow. R&D suppliers will be selected based on a public tender all along this PCP process in 3 phases according to the best-value for money solution. The 3 phases foresee the leverage of 4 technical modules (pre-analytics, sequencing, bioinformatics, e-reporting/e-medication) and their standardized interfaces – from design (Phase 1) to prototypes (Phase 2), and full integration in Phase 3. At the end, this PCP will provide 2 fully integrated, standardized NGS workflows for routine diagnostics of common and rare cancers from adults to children. In order to enable broad implementation in healthcare systems throughout Europe and beyond and to increase benefit to patients a series of support activities are planned including communication and dissemination activities targeting a broad stakeholder community, development of training and education material for healthcare professionals and patients, health economic assessment and engagement with healthcare payers and policy makers.

Keywords

Programme(s)

Topic(s)

Call for proposal

H2020-SC1-BHC-2018-2020

See other projects for this call

Sub call

H2020-SC1-2019-Single-Stage-RTD

Funding Scheme

PCP -

Coordinator

MEDIZINISCHE UNIVERSITAT GRAZ
Net EU contribution
€ 8 140 561,32
Address
Neue stiftingtalstrasse 6
8010 Graz
Austria

See on map
Region
Südösterreich Steiermark Graz
Activity type
Higher or Secondary Education Establishments
Links
Other funding
€ 904 506,81

Participants (21)

Share this page

Download

EC signature date 13 December 2019
Last update: 13 September 2023

My Booklet

Permalink: https://cordis.europa.eu/project/id/874719

European Union, 2023